241 related articles for article (PubMed ID: 29477208)
21. Safety of Proton Pump Inhibitors Based on a Large, Multi-Year, Randomized Trial of Patients Receiving Rivaroxaban or Aspirin.
Moayyedi P; Eikelboom JW; Bosch J; Connolly SJ; Dyal L; Shestakovska O; Leong D; Anand SS; Störk S; Branch KRH; Bhatt DL; Verhamme PB; O'Donnell M; Maggioni AP; Lonn EM; Piegas LS; Ertl G; Keltai M; Bruns NC; Muehlhofer E; Dagenais GR; Kim JH; Hori M; Steg PG; Hart RG; Diaz R; Alings M; Widimsky P; Avezum A; Probstfield J; Zhu J; Liang Y; Lopez-Jaramillo P; Kakkar AK; Parkhomenko AN; Ryden L; Pogosova N; Dans AL; Lanas F; Commerford PJ; Torp-Pedersen C; Guzik TJ; Vinereanu D; Tonkin AM; Lewis BS; Felix C; Yusoff K; Metsarinne KP; Fox KAA; Yusuf S;
Gastroenterology; 2019 Sep; 157(3):682-691.e2. PubMed ID: 31152740
[TBL] [Abstract][Full Text] [Related]
22. Major Adverse Limb Events and Mortality in Patients With Peripheral Artery Disease: The COMPASS Trial.
Anand SS; Caron F; Eikelboom JW; Bosch J; Dyal L; Aboyans V; Abola MT; Branch KRH; Keltai K; Bhatt DL; Verhamme P; Fox KAA; Cook-Bruns N; Lanius V; Connolly SJ; Yusuf S
J Am Coll Cardiol; 2018 May; 71(20):2306-2315. PubMed ID: 29540326
[TBL] [Abstract][Full Text] [Related]
23. Mortality Benefit of Rivaroxaban Plus Aspirin in Patients With Chronic Coronary or Peripheral Artery Disease.
Eikelboom JW; Bhatt DL; Fox KAA; Bosch J; Connolly SJ; Anand SS; Avezum A; Berkowitz SD; Branch KRH; Dagenais GR; Félix C; Guzik TJ; Hart RG; Maggioni AP; Muehlhofer E; Sharma M; Shestakovska O; Yusuf S
J Am Coll Cardiol; 2021 Jul; 78(1):14-23. PubMed ID: 34210409
[TBL] [Abstract][Full Text] [Related]
24. Major Bleeding in Patients With Coronary or Peripheral Artery Disease Treated With Rivaroxaban Plus Aspirin.
Eikelboom JW; Bosch JJ; Connolly SJ; Shestakovska O; Dagenais GR; Hart RG; Leong DP; O'Donnell M; Fox KAA; Bhatt DL; Cairns JA; Tasto C; Berkowitz SD; Cook Bruns N; Muehlhofer E; Diaz R; Maggioni AP; Yusuf S
J Am Coll Cardiol; 2019 Sep; 74(12):1519-1528. PubMed ID: 31537259
[TBL] [Abstract][Full Text] [Related]
25. Rivaroxaban With or Without Aspirin in Patients With Heart Failure and Chronic Coronary or Peripheral Artery Disease.
Branch KR; Probstfield JL; Eikelboom JW; Bosch J; Maggioni AP; Cheng RK; Bhatt DL; Avezum A; Fox KAA; Connolly SJ; Shestakovska O; Yusuf S
Circulation; 2019 Aug; 140(7):529-537. PubMed ID: 31163978
[TBL] [Abstract][Full Text] [Related]
26. Antithrombotic treatment in peripheral artery disease.
Olinic DM; Tataru DA; Homorodean C; Spinu M; Olinic M
Vasa; 2018 Feb; 47(2):99-108. PubMed ID: 29160765
[TBL] [Abstract][Full Text] [Related]
27. Optimizing the Safe Use of Direct Oral Anticoagulants in Older Patients: A Teachable Moment.
Sennesael AL; Dogné JM; Spinewine A
JAMA Intern Med; 2015 Oct; 175(10):1608-9. PubMed ID: 26237648
[No Abstract] [Full Text] [Related]
28. After revascularization for PAD, rivaroxaban reduced vascular events with a small increase in major bleeding.
Mukherjee D
Ann Intern Med; 2020 Aug; 173(4):JC22. PubMed ID: 32805167
[TBL] [Abstract][Full Text] [Related]
29. Efficacy and safety of adding rivaroxaban to the anti-platelet regimen in patients with coronary artery disease: a systematic review and meta-analysis of randomized controlled trials.
Yuan J
BMC Pharmacol Toxicol; 2018 May; 19(1):19. PubMed ID: 29720261
[TBL] [Abstract][Full Text] [Related]
30. Advances in the Treatment of Stable Coronary Artery Disease and Peripheral Artery Disease.
Gibler WB
Crit Pathw Cardiol; 2018 Jun; 17(2):53-68. PubMed ID: 29768312
[No Abstract] [Full Text] [Related]
31. Rivaroxaban: A New Treatment Paradigm in the Setting of Vascular Protection?
Bauersachs R; Zannad F
Thromb Haemost; 2018 May; 118(S 01):S12-S22. PubMed ID: 29566413
[TBL] [Abstract][Full Text] [Related]
32. Patients with Peripheral Artery Disease in the COMPASS Trial.
Kruger PC; Anand SS; de Vries TAC; Eikelboom JW
Eur J Vasc Endovasc Surg; 2018 Dec; 56(6):772-773. PubMed ID: 30213508
[No Abstract] [Full Text] [Related]
33. Triple therapy: worth the risk?
Wernly B; Lichtenauer M; Hoppe UC; Lauten A; Navarese EP; Jung C
Minerva Med; 2018 Oct; 109(5):403-405. PubMed ID: 30338683
[No Abstract] [Full Text] [Related]
34. Low-Dose Rivaroxaban Plus Aspirin in Patients With Peripheral Artery Disease Undergoing Lower Extremity Revascularization With and Without Concomitant Coronary Artery Disease: Insights From VOYAGER PAD.
Morrison JT; Canonico ME; Anand SS; Patel MR; Debus ES; Nehler MR; Hess CN; Hsia J; Capell WH; Muehlhofer E; Haskell LP; Berkowitz SD; Bauersachs RM; Bonaca MP
Circulation; 2024 May; 149(19):1536-1539. PubMed ID: 38709838
[No Abstract] [Full Text] [Related]
35. Synergistic influence of rivaroxaban on inflammation and coagulation biomarkers in patients with coronary artery disease and peripheral artery disease on aspirin therapy.
Tantry U; Cummings C; Mackrell P; Gonze M; Ulloa K; Bafford R; Rout A; Sukhi A; Gurbel P
Future Cardiol; 2020 Mar; 16(2):69-75. PubMed ID: 32129681
[TBL] [Abstract][Full Text] [Related]
36. External applicability of the COMPASS trial: the Western Denmark Heart Registry.
Würtz M; Olesen KKW; Thim T; Kristensen SD; Eikelboom JW; Maeng M
Eur Heart J Cardiovasc Pharmacother; 2019 Oct; 5(4):192-199. PubMed ID: 30916315
[TBL] [Abstract][Full Text] [Related]
37. Antithrombotic Therapy After Revascularization in Patients With Peripheral Arterial Disease: What Is Here, What Is Next.
Amer MR; Chaturvedula ST; Joshi S; Ingrassia J
Vasc Endovascular Surg; 2019 May; 53(4):325-336. PubMed ID: 30885060
[TBL] [Abstract][Full Text] [Related]
38. Role of rivaroxaban in the prevention of atherosclerotic events.
Sanmartín M; Bellmunt S; Cosín-Sales J; García-Moll X; Riera-Mestre A; Almendro-Delia M; Hernández JL; Lozano F; Mazón P; Suarez Fernández C
Expert Rev Clin Pharmacol; 2019 Aug; 12(8):771-780. PubMed ID: 31269825
[No Abstract] [Full Text] [Related]
39. Which oral anticoagulant for atrial fibrillation.
Med Lett Drugs Ther; 2016 Apr; 58(1492):45-6. PubMed ID: 27049507
[No Abstract] [Full Text] [Related]
40. Anti-thrombotic options for secondary prevention in patients with chronic atherosclerotic vascular disease: what does COMPASS add?
Fox KAA; Eikelboom JW; Anand SS; Bhatt DL; Bosch J; Connolly SJ; Harrington RA; Steg PG; Yusuf S
Eur Heart J; 2019 May; 40(18):1466-1471. PubMed ID: 29945212
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
